Do analysts prefer BNBX or RNAZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Dna Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate BDRX or BNBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Dna Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BDRX or BNBX?

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Applied Dna Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biodexa Pharmaceuticals $470K 3.33 -$8.42M N/A N/A Applied Dna Sciences $2.09M 0.50 -$15.16M -$36.76 N/A

Do analysts prefer BNBX or GOVX?

GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 20,791.36%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Applied Dna Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Dna Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend PPCB or BNBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Dna Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Applied Dna Sciences (BNBX) Competitors

$0.14 0.00 (0.00%)

As of 08/14/2026 03:53 PM Eastern

Compare

BNBX vs. CLGN, RNAZ, BDRX, GOVX, and PPCB

Should you buy Applied Dna Sciences stock or one of its competitors? Applied Dna Sciences's main competitors and comparable companies include CollPlant Biotechnologies (CLGN), TransCode Therapeutics (RNAZ), Biodexa Pharmaceuticals (BDRX), GeoVax Labs (GOVX), and Propanc Biopharma (PPCB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Applied Dna Sciences compare to CollPlant Biotechnologies?

CollPlant Biotechnologies (NASDAQ:CLGN) and Applied Dna Sciences (NASDAQ:BNBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

CollPlant Biotechnologies has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Applied Dna Sciences has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

CollPlant Biotechnologies has higher revenue and earnings than Applied Dna Sciences. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37M	2.01	-$11.49M	-$1.45	N/A
Applied Dna Sciences	$2.09M	0.50	-$15.16M	-$36.76	N/A

In the previous week, CollPlant Biotechnologies had 1 more articles in the media than Applied Dna Sciences. MarketBeat recorded 2 mentions for CollPlant Biotechnologies and 1 mentions for Applied Dna Sciences. CollPlant Biotechnologies' average media sentiment score of 0.94 beat Applied Dna Sciences' score of -0.95 indicating that CollPlant Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
CollPlant Biotechnologies	Positive
Applied Dna Sciences	Negative

CollPlant Biotechnologies currently has a consensus target price of $11.50, suggesting a potential upside of 3,388.02%. Given CollPlant Biotechnologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe CollPlant Biotechnologies is more favorable than Applied Dna Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Applied Dna Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 22.2% of Applied Dna Sciences shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by insiders. Comparatively, 6.1% of Applied Dna Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CollPlant Biotechnologies has a net margin of -683.68% compared to Applied Dna Sciences' net margin of -1,647.25%. CollPlant Biotechnologies' return on equity of -218.81% beat Applied Dna Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%

Summary

CollPlant Biotechnologies beats Applied Dna Sciences on 14 of the 16 factors compared between the two stocks.

How does Applied Dna Sciences compare to TransCode Therapeutics?

Applied Dna Sciences (NASDAQ:BNBX) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Applied Dna Sciences has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, TransCode Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

TransCode Therapeutics has a net margin of 0.00% compared to Applied Dna Sciences' net margin of -1,647.25%. Applied Dna Sciences' return on equity of -349.95% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%
TransCode Therapeutics	N/A	-1,027.46%	-41.16%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Dna Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, TransCode Therapeutics had 1 more articles in the media than Applied Dna Sciences. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Applied Dna Sciences. TransCode Therapeutics' average media sentiment score of 1.48 beat Applied Dna Sciences' score of -0.95 indicating that TransCode Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Dna Sciences	Negative
TransCode Therapeutics	Positive

Applied Dna Sciences has higher revenue and earnings than TransCode Therapeutics. TransCode Therapeutics is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Dna Sciences	$2.09M	0.50	-$15.16M	-$36.76	N/A
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A

22.2% of Applied Dna Sciences shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by company insiders. Comparatively, 0.1% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Applied Dna Sciences beats TransCode Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Applied Dna Sciences compare to Biodexa Pharmaceuticals?

Biodexa Pharmaceuticals (NASDAQ:BDRX) and Applied Dna Sciences (NASDAQ:BNBX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.2% of Applied Dna Sciences shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 6.1% of Applied Dna Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodexa Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Dna Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biodexa Pharmaceuticals has higher earnings, but lower revenue than Applied Dna Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodexa Pharmaceuticals	$470K	3.33	-$8.42M	N/A	N/A
Applied Dna Sciences	$2.09M	0.50	-$15.16M	-$36.76	N/A

Biodexa Pharmaceuticals has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Applied Dna Sciences has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

Biodexa Pharmaceuticals has a net margin of 0.00% compared to Applied Dna Sciences' net margin of -1,647.25%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Applied Dna Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodexa Pharmaceuticals	N/A	N/A	N/A
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%

In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Applied Dna Sciences. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Applied Dna Sciences. Biodexa Pharmaceuticals' average media sentiment score of 0.44 beat Applied Dna Sciences' score of -0.95 indicating that Biodexa Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Biodexa Pharmaceuticals	Neutral
Applied Dna Sciences	Negative

Summary

Biodexa Pharmaceuticals beats Applied Dna Sciences on 8 of the 11 factors compared between the two stocks.

How does Applied Dna Sciences compare to GeoVax Labs?

Applied Dna Sciences (NASDAQ:BNBX) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

22.2% of Applied Dna Sciences shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 6.1% of Applied Dna Sciences shares are owned by company insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Applied Dna Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.73, meaning that its stock price is 273% more volatile than the broader market.

GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 20,791.36%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Applied Dna Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Dna Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

GeoVax Labs has a net margin of 0.00% compared to Applied Dna Sciences' net margin of -1,647.25%. Applied Dna Sciences' return on equity of -349.95% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%
GeoVax Labs	N/A	-743.64%	-394.74%

In the previous week, GeoVax Labs had 4 more articles in the media than Applied Dna Sciences. MarketBeat recorded 5 mentions for GeoVax Labs and 1 mentions for Applied Dna Sciences. GeoVax Labs' average media sentiment score of 0.57 beat Applied Dna Sciences' score of -0.95 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Dna Sciences	Negative
GeoVax Labs	Positive

Applied Dna Sciences has higher earnings, but lower revenue than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Dna Sciences	$2.09M	0.50	-$15.16M	-$36.76	N/A
GeoVax Labs	$2.49M	1.00	-$21.47M	-$11.34	N/A

Summary

GeoVax Labs beats Applied Dna Sciences on 9 of the 15 factors compared between the two stocks.

How does Applied Dna Sciences compare to Propanc Biopharma?

Propanc Biopharma (NASDAQ:PPCB) and Applied Dna Sciences (NASDAQ:BNBX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Dna Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Applied Dna Sciences has higher revenue and earnings than Propanc Biopharma. Propanc Biopharma is trading at a lower price-to-earnings ratio than Applied Dna Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A
Applied Dna Sciences	$2.09M	0.50	-$15.16M	-$36.76	N/A

Propanc Biopharma has a beta of 3.52, meaning that its share price is 252% more volatile than the broader market. Comparatively, Applied Dna Sciences has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

22.2% of Applied Dna Sciences shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by company insiders. Comparatively, 6.1% of Applied Dna Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Propanc Biopharma has a net margin of 0.00% compared to Applied Dna Sciences' net margin of -1,647.25%. Propanc Biopharma's return on equity of -151.28% beat Applied Dna Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-151.28%	-109.53%
Applied Dna Sciences	-1,647.25%	-349.95%	-283.96%

In the previous week, Propanc Biopharma had 3 more articles in the media than Applied Dna Sciences. MarketBeat recorded 4 mentions for Propanc Biopharma and 1 mentions for Applied Dna Sciences. Propanc Biopharma's average media sentiment score of 0.72 beat Applied Dna Sciences' score of -0.95 indicating that Propanc Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Propanc Biopharma	Positive
Applied Dna Sciences	Negative

Summary

Propanc Biopharma beats Applied Dna Sciences on 8 of the 12 factors compared between the two stocks.

Get Applied Dna Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNBX vs. The Competition

Export

Metric	Applied Dna Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.04M	$3.72B	$7.00B	$13.04B
Dividend Yield	N/A	3.68%	2.56%	10.42%
P/E Ratio	0.00	10.83	271.56	25.35
Price / Sales	0.50	1,296.41	604.96	100.03
Price / Cash	N/A	45.24	28.87	38.43
Price / Book	0.10	17.55	11.22	6.52
Net Income	-$15.16M	-$13.33M	$3.45B	$346.81M
7 Day Performance	7.25%	1.31%	1.02%	1.27%
1 Month Performance	21.34%	2.64%	2.35%	2.57%
1 Year Performance	N/A	54.05%	62.40%	20.83%

Applied Dna Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNBX Applied Dna Sciences	0.0541 of 5 stars	$0.15 flat	N/A	N/A	$1.04M	$2.09M	N/A	70	Earnings Report Gap Down
CLGN CollPlant Biotechnologies	3.0312 of 5 stars	$0.32 +8.2%	$11.50 +3,501.6%	-87.1%	$4.26M	$2.37M	N/A	70	Positive News Upcoming Earnings Gap Up
RNAZ TransCode Therapeutics	1.2202 of 5 stars	$3.37 -1.7%	N/A	-69.6%	$3.63M	N/A	N/A	9	Earnings Report Upcoming Earnings
BDRX Biodexa Pharmaceuticals	0.345 of 5 stars	$1.50 -5.1%	N/A	-95.7%	$3.15M	$470K	N/A	20	Short Interest Increase Gap Down
GOVX GeoVax Labs	3.1414 of 5 stars	$0.73 -5.8%	$150.00 +20,572.5%	-96.2%	$2.67M	$2.49M	N/A	10	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNBX) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Dna Sciences (BNBX) Competitors

BNBX vs. CLGN, RNAZ, BDRX, GOVX, and PPCB

How does Applied Dna Sciences compare to CollPlant Biotechnologies?

Summary

How does Applied Dna Sciences compare to TransCode Therapeutics?

Summary

How does Applied Dna Sciences compare to Biodexa Pharmaceuticals?

Summary

How does Applied Dna Sciences compare to GeoVax Labs?

Summary

How does Applied Dna Sciences compare to Propanc Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNBX vs. The Competition

Applied Dna Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Dna Sciences (BNBX) Competitors

BNBX vs. CLGN, RNAZ, BDRX, GOVX, and PPCB

How does Applied Dna Sciences compare to CollPlant Biotechnologies?

Which has more volatility & risk, CLGN or BNBX?

Which has preferable earnings and valuation, CLGN or BNBX?

Does the media refer more to CLGN or BNBX?

Do analysts recommend CLGN or BNBX?

Do insiders and institutionals hold more shares of CLGN or BNBX?

Is CLGN or BNBX more profitable?

Summary

How does Applied Dna Sciences compare to TransCode Therapeutics?

Which has more risk & volatility, BNBX or RNAZ?

Is BNBX or RNAZ more profitable?

Do analysts prefer BNBX or RNAZ?

Does the media refer more to BNBX or RNAZ?

Which has preferable valuation & earnings, BNBX or RNAZ?

Do insiders & institutionals have more ownership in BNBX or RNAZ?

Summary

How does Applied Dna Sciences compare to Biodexa Pharmaceuticals?

Do institutionals & insiders believe in BDRX or BNBX?

Do analysts rate BDRX or BNBX?

Which has stronger earnings & valuation, BDRX or BNBX?

Which has more volatility and risk, BDRX or BNBX?

Is BDRX or BNBX more profitable?

Does the media prefer BDRX or BNBX?

Summary

How does Applied Dna Sciences compare to GeoVax Labs?

Do institutionals and insiders hold more shares of BNBX or GOVX?

Which has more risk and volatility, BNBX or GOVX?

Do analysts prefer BNBX or GOVX?

Is BNBX or GOVX more profitable?

Does the media favor BNBX or GOVX?

Which has preferable earnings and valuation, BNBX or GOVX?

Summary

How does Applied Dna Sciences compare to Propanc Biopharma?

Do analysts recommend PPCB or BNBX?

Which has preferable earnings & valuation, PPCB or BNBX?

Which has more risk & volatility, PPCB or BNBX?

Do institutionals and insiders hold more shares of PPCB or BNBX?

Is PPCB or BNBX more profitable?

Does the media refer more to PPCB or BNBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNBX vs. The Competition

Applied Dna Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools